European and International Collaborations Sample Clauses

European and International Collaborations. The EMI project vision and mission are part of a more general context of European and international collaborations. The interaction of relevant initiatives and the cross-fertilization of ideas are essential to achieve the proposed objectives. EMI has therefore already started discussions and exchanges of ideas and joint collaborations with a number of existing and proposed projects in various fields. Most notably the following collaborations have been discussed: EMI in terms of what services must be supported. A letter of support from NDGF is provided in Appendix X. In addition, a number of projects have expressed a strong interest in making use of the software certification process that EMI will establish in support of its own engineering process. EMI is in favour of providing its tools, procedures and expertise to third-party projects with the two-fold goal of enforcing the correct integration of applications and tools with the EMI middleware and strengthening the reliability of the certification procedure through external contribution and review of functional and compliance test suites. Access to the EMI certification process will be granted on the base of Memorandums of Understanding as part of the ‗Works with EMI‘ collaboration program. EMI is committed to establish a functional Distributed Computing Infrastructures (DCI) ecosystem where all the relevant projects and activities can provide specific expertise and results. To this effect work has been started with EGI, VENUS-C, Xxxxxxxxxx, EDGI and IGE with the collaboration of the SIENA project to understand the relationships among the projects and any opportunity for collaboration within the larger scope of a coherent European Roadmap to be coordinated by the European Commission. The initial collaboration has two specific goals: 1) To provide a preliminary definition of the roadmap and position each project in it by assessing its specific areas of expertise and its objectives. 2) To establish bi-lateral or multi-lateral channels between the individual projects, so that more detailed common work plans can be defined within the context of the common roadmap Specific effort is allocated to this activity in the EMI project. The preliminary work will be carried out very early in the project lifetime in order to establish as early as possible a practical work plan for the duration of the project. The common objectives and roadmap and the identified opportunities for collaborations will therefore be describe...
Sample 1Sample 2Sample 3See All (4)
AutoNDA by SimpleDocs
European and International Collaborations where the relationships with the other DCI projects and beyond have been described. This section has been now expanded with additional text Done describing the current proposed strategy for establishing practical objectives work plans in the context of a more general European roadmap. The strategy has been elaborated already in concertation with the other DCI projects. A new deliverable describing in detail the roadmap and the work plans has been added to the NA1 activity at PM6 (DNA1.4 - EMI Roadmap and DCI Collaborations) 8 The DoW will include a revised plan for the milestones and deliverables covering the security area in views of ensuring that steps on security integration are taken earlier in time compared to what was described in the project proposal. An initial discussion on the security architecture and the rules for its evolution will be part of the DoW and in any case will be fully defined before actual developments take place The relevant security milestones and deliverables have been moved very early in the project and an additional milestone (Security Workshop) has been added at PM2 at the latest, to gather all experts from EMI and other projects and work out the details of the work plan to be followed in EMI. The security strategy description has been revised in the JRA1 WP description and aligned with the goal of finalizing the security architecture before any actual development takes place Done 3.1 Methodology to achieve the objectives of the project, in particular the provision of integrated services” and in section “B2.1 Management structure and procedures”. The description of the Engineering Management Team has also been added as the body responsible for the day-to- day technical management of the EMI releases Done 10 The DoW will include initial ideas for a more ambitious dissemination and exploitation plan of the project The Outreach and Dissemination work package section has been substantially reviewed to describe the relationships Done results compared to what was described in the project proposal with user communities, the ESFRI projects and public and media.
Sample 1
European and International Collaborations. The EMI project vision and mission are part of a more general context of European and international collaborations. The interaction of relevant initiatives and the cross-fertilization of ideas are essential to achieve the proposed objectives. EMI has therefore already started discussions and exchanges of ideas and joint collaborations with a number of existing and proposed projects in various fields. Most notably the following collaborations have been discussed: EMI in terms of what services must be supported. A letter of support from NDGF is provided in Appendix X. In addition, a number of projects have expressed a strong interest in making use of the software certification process that EMI will establish in support of its own engineering process. EMI is in favour of providing its tools, procedures and expertise to third-party projects with the two-fold goal of enforcing the correct integration of applications and tools with the EMI middleware and strengthening the reliability of the certification procedure through external contribution and review of functional and compliance test suites. Access to the EMI certification process will be granted on the base of Memorandums of Understanding as part of the ‗Works with EMI‘ collaboration program. EMI is committed to establish a functional Distributed Computing Infrastructures (DCI) ecosystem where all the relevant projects and activities can provide specific expertise and results. To this effect work has been started with EGI, VENUS-C, Xxxxxxxxxx, EDGI and IGE with the collaboration of the SIENA project to understand the relationships among the projects and any opportunity for collaboration within the larger scope of a coherent European Roadmap to be coordinated by the European Commission. The initial collaboration has two specific goals:
Sample 1

Related to European and International Collaborations

  • Definitions of General Application For purposes of this Agreement, unless otherwise specified: Agreement means the Free Trade Agreement between the Government of the People's Republic of China and the Government of the Republic of Peru; Commission means the Free Trade Commission established under Article 170 (Free Trade Commission) of Chapter 14 (Administration of the Agreement);

  • International Olympic Committee; International Red Cross and Red Crescent Movement As instructed from time to time by ICANN, the names (including their IDN variants, where applicable) relating to the International Olympic Committee, International Red Cross and Red Crescent Movement listed at xxxx://xxx.xxxxx.xxx/en/resources/registries/reserved shall be withheld from registration or allocated to Registry Operator at the second level within the TLD. Additional International Olympic Committee, International Red Cross and Red Crescent Movement names (including their IDN variants) may be added to the list upon ten (10) calendar days notice from ICANN to Registry Operator. Such names may not be activated in the DNS, and may not be released for registration to any person or entity other than Registry Operator. Upon conclusion of Registry Operator’s designation as operator of the registry for the TLD, all such names withheld from registration or allocated to Registry Operator shall be transferred as specified by ICANN. Registry Operator may self-­‐allocate and renew such names without use of an ICANN accredited registrar, which will not be considered Transactions for purposes of Section 6.1 of the Agreement.

  • Development and Commercialization Subject to Sections 4.6 and 4.7, Fibrocell shall be solely responsible for the development and Commercialization of Fibrocell Products and Improved Products. Fibrocell shall be responsible for all costs incurred in connection with the Fibroblast Program except that Intrexon shall be responsible for the following: (a) costs of establishing manufacturing capabilities and facilities in connection with Intrexon’s manufacturing obligation under Section 4.6 (provided, however, that Intrexon may include an allocable portion of such costs, through depreciation and amortization, when calculating the Fully Loaded Cost of manufacturing a Fibrocell Product, to the extent such allocation, depreciation, and amortization is permitted by US GAAP, it being recognized that the majority of non-facilities scale-up costs cannot be capitalized and amortized under US GAAP); (b) costs of basic research with respect to the Intrexon Channel Technology and Intrexon Materials (i.e., platform improvements) but, for clarity, excluding research described in Section 4.7 or research requested by the JSC for the development of a Fibrocell Product or an Improved Product (which research costs shall be reimbursed by Fibrocell); (c) [*****]; and (d) costs of filing, prosecution and maintenance of Intrexon Patents. The costs encompassed within subsection (a) above shall include the scale-up of Intrexon Materials and related active pharmaceutical ingredients for clinical trials and Commercialization of Fibrocell Products undertaken pursuant to Section 4.6, which shall be at Intrexon’s cost whether it elects to conduct such efforts internally or through Third Party contractors retained by either Intrexon or Fibrocell (with Intrexon’s consent).

  • General Application The rules set forth below in this Article VI shall apply for the purposes of determining each Member’s allocable share of the items of income, gain, loss and expense of the Company comprising Net Income or Net Loss for each Fiscal Year, determining special allocations of other items of income, gain, loss and expense, and adjusting the balance of each Member’s Capital Account to reflect the aforementioned general and special allocations. For each Fiscal Year, the special allocations in Section 6.03 hereof shall be made immediately prior to the general allocations of Section 6.02 hereof.

  • Other Provisions of General Application Section 7.1 Notices to the Rights Agent, Parent and the Stockholders’ Representative. Any notice, request, instruction or other document to be given hereunder by any party to the others shall be in writing and delivered personally or sent by registered or certified mail, postage prepaid, by electronic mail (except with respect to the Rights Agent), by facsimile transmission only with respect to the Rights Agent or overnight courier, provided that with respect to notices deliverable to the Stockholders’ Representative, such notices shall be delivered solely via electronic mail or facsimile: If to Parent or the Company: Eros International Plc First Names House Victoria Road Xxxxxxx Isle of Man IM2 4DF British Isles Attention: Xxxx Xxxxxxx, Chief Corporate and Strategy Officer Email: xxxx.xxxxxxx@xxxxxxxx.xxx with a copy (which shall not constitute notice) to: Xxxxxx, Xxxx & Xxxxxxxx LLP 000 Xxxxx Xxxxx Xxxxxx Xxx Xxxxxxx, Xxxxxxxxxx 00000-0000 Attention: Xxxxx Xxxxxx Xxxxx Xxxxxx Email: xxxxxxx@xxxxxxxxxx.xxx xxxxxxx@xxxxxxxxxx.xxx If to the Rights Agent: Computershare Trust Company, N.A., Computershare Inc. 000 Xxxxxx Xxxxxx Canton, MA 02021 Attention: Client Services Facsimile: (000) 000-0000 If to the Stockholders’ Representative: Fortis Advisors LLC Attention: Notices Department (Project World Cup) Email: xxxxxxx@xxxxxxxxx.xxx Facsimile: (000) 000-0000 with a copy (which shall not constitute notice) to: Xxxxxxxx & Xxxxx LLP 000 Xxxxx Xxxxxx Xxxxxx, Xxxxx 0000 Xxx Xxxxxxx, Xxxxxxxxxx 00000 Attention: Xxxx X. Xxxxxx, P.C. Email: xxxx.xxxxxx@xxxxxxxx.xxx or to such other persons or addresses as may be designated in writing by the party to receive such notice as provided above. Any notice, request, instruction or other document given as provided above shall be deemed given to the receiving party upon actual receipt, if delivered personally; three (3) business days after deposit in the mail, if sent by registered or certified mail; upon confirmation of successful transmission if sent by electronic mail; or on the next business day after deposit with an overnight courier, if sent by an overnight courier.

  • Commercialization Reports Throughout the term of this Agreement and during the Sell-Off Period, and within thirty (30) days of December 31st of each year, Company will deliver to University written reports of Company’s and Sublicensees’ efforts and plans to develop and commercialize the innovations covered by the Licensed Rights and to make and sell Licensed Products. Company will have no obligation to prepare commercialization reports in years where (a) Company delivers to University a written Sales Report with active sales, and (b) Company has fulfilled all Performance Milestones. In relation to each of the Performance Milestones each commercialization report will include sufficient information to demonstrate achievement of those Performance Milestones and will set out timeframes and plans for achieving those Performance Milestones which have not yet been met.

  • Provisions of General Application (a) All accounting terms not specifically defined herein shall be construed in accordance with GAAP. (b) The terms defined in this Article include the plural as well as the singular. (c) The words "herein," "hereof" and "hereunder" and other words of similar import refer to this Agreement as a whole. All references to Articles and Sections shall be deemed to refer to Articles and Sections of this Agreement.

  • Other Methods of Procurement of Goods and Works The following table specifies the methods of procurement, other than International Competitive Bidding, which may be used for goods and works. The Procurement Plan shall specify the circumstances under which such methods may be used: (a) National Competitive Bidding (b) Shopping (c) Direct Contracting

  • Commercialization Plan (a) Not later than three [***] after submission of Regulatory Filings for each Product in each country of the Territory, Licensee will provide to the JCC for review its initial Commercialization Plan for each Product for each country in the Territory. Such initial Commercialization Plan will describe Licensee’s plans for activities to be conducted for such Product for such country. Each Commercialization Plan shall include the details of obligations to be performed by Licensee to achieve the specific activities that are applicable to the stage of [***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. Commercialization (e.g., pre-launch, launch planning, launch, or post-launch) of the applicable Product during the time period covered by such Commercialization Plan and subsequent time periods. (b) Prior to the First Commercial Sale for such Product in such country, Licensee will provide to the JCC for review an updated Commercialization Plan for such Product for such country. Such updated Commercialization Plan will include, but not be limited to, Licensee’s updated plans for activities to be conducted for such Product for such country prior to launch as well as activities to be conducted in connection with such launch. (c) Promptly after each anniversary of the First Commercial Sale of such Product during the Term, Licensee will provide to the JCC for review updated Commercialization Plans for such Product for such country. Such further updated Commercialization Plan will include, but not be limited to, Licensee’s plans for Commercialization activities for such Product and such country for the twelve (12) month period following the date of delivery of such Commercialization Plan. No Commercialization Plan may be implemented by Licensee if [***]. Each Commercialization Plan shall be consistent with and shall not contradict the terms of this Agreement [***], and in the event of any inconsistency between the Commercialization Plan and this Agreement, the terms of this Agreement shall prevail. Notwithstanding the foregoing, if a [***], Licensee shall [***] and shall promptly [***].

  • Clinical Trials The studies, tests and preclinical and clinical trials conducted by or on behalf of, or sponsored by, the Company, or in which the Company has participated, that are described in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, or the results of which are referred to in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, were and, if still pending, are being conducted in all material respects in accordance with protocols, procedures and controls pursuant to, where applicable, accepted professional and scientific standards for products or product candidates comparable to those being developed by the Company and all applicable statutes, rules and regulations of the FDA, the EMEA, Health Canada and other comparable drug and medical device (including diagnostic product) regulatory agencies outside of the United States to which they are subject; the descriptions of the results of such studies, tests and trials contained in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus do not contain any misstatement of a material fact or omit a material fact necessary to make such statements not misleading; the Company has no knowledge of any studies, tests or trials not described in the Disclosure Package and the Prospectus the results of which reasonably call into question in any material respect the results of the studies, tests and trials described in the Registration Statement, the Time of Sale Disclosure Package or Prospectus; and the Company has not received any notices or other correspondence from the FDA, EMEA, Health Canada or any other foreign, state or local governmental body exercising comparable authority or any Institutional Review Board or comparable authority requiring or threatening the termination, suspension or material modification of any studies, tests or preclinical or clinical trials conducted by or on behalf of, or sponsored by, the Company or in which the Company has participated, and, to the Company’s knowledge, there are no reasonable grounds for the same. Except as disclosed in the Registration Statement, the Time of Sale Disclosure Package and the Prospectus, there has not been any violation of law or regulation by the Company in its respective product development efforts, submissions or reports to any regulatory authority that could reasonably be expected to require investigation, corrective action or enforcement action.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!